The case of José Baselga and his undisclosed payments of millions of dollars is generating much needed discussion on conflicts of interest and academic leadership. The lay press and *The New York Times* in particular have vilified industry‐physician relationships and cast aspersions on all such endeavors with a focus on the corrupting influences of industry payments on health care as a whole.

In academic medicine, working with industry partners is often required for progress. No academic institution is capitalized to fund drug development or large clinical trials. Although the NCI‐funded cooperative groups are essential, they are woefully underfunded. Cooperative groups will never provide more than a sliver of our clinical trial needs. Moving the needle at the FDA typically requires a coordinated effort involving many millions of dollars, and changing practice requires expensive practice‐changing trials that physicians can rarely (if ever) afford to implement on their own.

Many but not all successful academic clinicians cooperate with industry to ensure advances occur more quickly. Industry knows patents, composition of matter, manufacturing, and databases and has access to capital. Academics know the disease, the patients, the nuances of clinical trial design, and the context of each treatment.

Cooperation between industry and academics is essential for optimal drug development. Influencing industry in a positive way is part of what academics can and should be doing. Industry, left to its own devices, is likely to disproportionately prioritize financial goals. Academics can help to set goals and missions that are more explicitly patient and pathophysiology focused. Furthermore, academics often can provide insights into disease processes in a manner that catalyzes the next series of advances.

Disclosures are necessary and required but are not sufficient, nor can they always be taken at face value. Payments from companies to physicians may be an attempt to influence prescribing habits; however, payments from companies also may be necessary for engaging independent data monitor committees, analyzing complex data sets, designing large trials, or strategically defining promising new therapeutic opportunities. Academic physicians are experts in human health; their talents should be fully brought to bear on the biggest and most complex health issues our patients face, with partners who can make the biggest impact. How academic physicians positively influence pharmaceutical development is rarely discussed and often unappreciated.

Physicians can influence companies in many productive ways---ways that directly benefit patients and improve health care as a whole. Although it is certainly possible for academics to be pharmaceutical company dupes, that is less common than assumed by those outside the profession. Pharmaceutically influenced experts are readily dismissed by academic peers; those holding biased views typically damage their own credibility. Making unverified or biased claims typically provides a quick route to academic obscurity.

Keeping up with disclosures is more difficult than some might imagine. Greater consistency is needed, and a "one‐size‐fits‐all" approach might be best. Why should one journal differ from another in their disclosure requirements?

Will conflict of interest disclosures solve the problem perceived by many regarding the corrupting influence of industry in medicine? This editorialist doubts that to be the case. Industry will continue to pursue profitability and returns on investment regardless of how physicians practice. What is needed is transparency. When physicians are paid, rules should be evenly applied to those who present and publish. A national database and consistent guidelines would be steps in a positive direction. That said, immediate assumptions of guilt for those working with industry is not appropriate.

While there is much to be improved, and this is no apology for egregious disregard of conflict of interest disclosures, one should not entirely vilify the pharmaceutical/investigator relationship. Done properly, there is much to be gained for the sake of human health.
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